Article
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
JAMA cardiology - 1 Oct 2018
Lotta Luca A, Stewart Isobel D, Sharp Stephen J, Day Felix R, Burgess Stephen, Luan Jian'an, Bowker Nicholas, Cai Lina, Li Chen, Wittemans Laura B L, Kerrison Nicola D, Khaw Kay-Tee, McCarthy Mark I, O'Rahilly Stephen, Scott Robert A, Savage David B, Perry John R B, Langenberg Claudia, Wareham Nicholas J
Abstract excerpt
Importance: Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome trials. Human genetics studies can help prioritize or deprioritize these resource-demanding endeavors. Objective: To...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.